



AMENDMENTS TO THE CLAIMS

RECEIVED

APR 11 2003

TECH CENTER 1600/2900

Please amend Claims 30 and 31.

Claims 1-22 (Cancelled).

23. (Previously Added) A method of screening for candidate compounds capable of modulating the activity of a G-protein coupled receptor polypeptide, comprising:

- (a) contacting a test compound with a cell or tissue comprising an expression vector capable of expressing a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2, or encoded by ATCC deposit PTA-2966, under conditions in which said polypeptide is expressed; and
- (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.

24. (Previously Added) The method according to claim 23 wherein said cells are CHO cells.

25. (Previously Added) The method according to claim 23 wherein said cells comprise a vector comprising the coding sequence of the beta lactamase gene under the control of NFAT response elements.

26. (Previously Added) The method according to claim 25 wherein said cells further comprise a vector comprising the coding sequence of G alpha 15 under conditions wherein G alpha 15 is expressed.

27. (Withdrawn)

28. (Previously Added) The method according to claim 23 wherein said cells are HEK cells.

29. (Withdrawn)

30. (Currently Amended) The method according to claim 26 wherein said cells express the polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, or encoded by ATCC deposit PTA-2966, at low levels of expression relative to the expression of a reference polynucleotide.

31. (Currently Amended) The method according to claim 26 wherein said cells express the polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, or encoded by ATCC deposit PTA-2966, at high levels of expression relative to the expression of a reference polynucleotide.

32-33. (Withdrawn)

34. (Previously Added) The method according to claim 26 wherein said candidate compound is a small molecule.

35. (Previously Added) The method according to claim 26 wherein said candidate compound is a peptide.

36. (Previously Added) The method according to claim 26 wherein said candidate compound is an antisense molecule.

37-39. (Withdrawn)

40. (Previously Added) The method according to claim 26 wherein said candidate compound is an agonist.

41. (Previously Added) The method according to claim 26 wherein said candidate compound is an antagonist.

42-43. (Withdrawn)

44. (Previously Added) The method according to claim 26 wherein said candidate compound is useful for treating disorders of the caudate nucleus selected from the group consisting of: a neurological disorder; Parkinson's disease; neuropathic pain; psychotic disorders; severe mental retardation; dyskinesias, Huntington's disease; Gilles de la Tourette's syndrome; Sydenham chorea; major depressive disorder; obsessive-compulsive disorder; movement type disorders; anxiety; schizophrenia; manic depression; delirium; dementia; and neoplastic diseases of the brain.

45. (Previously Added) The method according to claim 26 wherein said cells express beta lactamase at low levels.

46. (Previously Added) The method according to claim 26 wherein said cells express beta lactamase at high levels.

47-48. (Withdrawn)

B1
cont